Skip to content

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

  • Home
  • About US
  • Bioinsight
  • Policy Hub
  • Deals Book
  • Privacy Policy
  • Contact US

Header Toggle Sidebar

This is an example widget to show how the Header Toggle Sidebar looks by default. You can add custom widgets from the widgets in the admin.

Company Deals

VectorBuilder and Lir Therapeutics Forge AI Collaboration to Optimize AAV Capsids for Clinical Translation

Fineline Cube Aug 20, 2026
Company Deals

LEO Pharma to Acquire Global Rights to Dersimelagon From Tanabe – Late‑Stage Oral Therapy for Rare Protoporphyrias Nears FDA Decision

Fineline Cube Aug 20, 2026
Company Deals

Bio-Thera Solutions Expands Partnership with Avalon Pharma: Exclusive MENA Licensing Deal for Dupixent Biosimilar BAT2406 – Second Collaboration After BAT3306

Fineline Cube Aug 19, 2026
Company Deals

OmniAb Signs Global Collaboration and License Agreement with Eli Lilly for Ion Channel Program – Up to $370 Million in Milestones Plus Royalties

Fineline Cube Aug 18, 2026
Company Deals

Navi Therapeutics Completes Angel and Series A Rounds Totaling Several Hundred Million RMB – Legend Capital Co‑Leads Backing for Next‑Generation ADC Platform

Fineline Cube Aug 18, 2026
Company Policy / Regulatory

China’s CDE Opens Public Comment on “Pioneer Program” for Cell and Gene Therapy Products, Capping Intake at 15 Drugs Per Year

Fineline Cube Aug 20, 2026
Company Drug

Abbisko Wins NMPA IND Clearance for Pan‑KRAS Inhibitor ABSK211 in Advanced Solid Tumors, Following FDA Green Light

Fineline Cube Aug 20, 2026
Company Drug

Haisco Pharmaceutical Wins NMPA Clinical Approval for Nav1.8 Inhibitor HSK51155 – Pain Drug Licensed to AbbVie in USD 700 Million Deal Advances in China

Fineline Cube Aug 19, 2026
Company Medical Device

MicroPort CardioFlow Medtech’s AnchorMan System Receives NMPA Approval as First Semi-Closed LAA Occluder in China

Fineline Cube Jan 8, 2024

MicroPort Scientific Corp (HKG: 0853), a leading medical device company based in China, has announced...

Company Deals

Ningbo Linstant Polymer Materials Secures Over USD 14 Million in Series B Financing to Boost Production and Global Reach

Fineline Cube Jan 8, 2024

Ningbo Linstant Polymer Materials Co., Ltd, a Chinese manufacturer specializing in polymer accessories for medical...

Company Deals

Lion TCR Partners with MaxCyte to Develop mRNA-Based TCR-T Therapies for Solid Tumors and Viral Diseases

Fineline Cube Jan 8, 2024

Lion TCR, a Singapore-based clinical-stage biotechnology company with backing from Chinese investors, has entered into...

Company Deals

OnCusp Therapeutics Secures Oversubscribed USD 100 Million Series A Financing for CDH6-Targeting ADC

Fineline Cube Jan 8, 2024

OnCusp Therapeutics, a U.S.-based biopharmaceutical company, has closed an oversubscribed Series A financing round, raising...

Company Deals

Merck In-Licenses Inspirna’s Ompenaclid for Advanced Colorectal Cancer, Eyes Market Potential

Fineline Cube Jan 5, 2024

Germany-based Merck (NYSE: MRK) has in-licensed the potential first-in-class candidate ompenaclid from U.S. firm Inspirna,...

Company Deals

Boehringer Ingelheim Teams Up with 3T Biosciences for Next-Gen T-Cell Cancer Therapies

Fineline Cube Jan 5, 2024

German pharmaceutical leader Boehringer Ingelheim (BI) has entered into a new agreement with U.S.-based 3T...

Company Deals

Novo Nordisk Expands U.S. Ties, Collaborates with Flagship Pioneering on Cardiometabolic Advances

Fineline Cube Jan 5, 2024

Danish pharmaceutical giant Novo Nordisk (NYSE: NVO) is advancing its U.S. partnerships by joining forces...

Company Deals

Menarini’s Stemline Signs $500M+ License with Insilico for Cancer Drug Candidate

Fineline Cube Jan 5, 2024

Italy’s Menarini Group, through its subsidiary Stemline Therapeutics, has entered an exclusive license agreement with...

Company Drug

Genrix Bio Seeks China Approval for New Xeligekimab Use in Axial Spondyloarthritis

Fineline Cube Jan 5, 2024

Chongqing Genrix Biopharmaceutical Co., Ltd. (SHA: 688443), a biopharmaceutical company based in China, has submitted...

Policy / Regulatory

Shanghai Pharmaceuticals’ Subsidiary Reprimanded Again for Monopolisitic Pricing of Polymyxin B Sulfate

Fineline Cube Jan 5, 2024

The Shanghai Administration for Market Regulation (AMR) bureau has once again reprimanded SHP No.1 Biomedical...

Company Drug

Akeso Biopharma Submits New Indication Application for Cadonilimab in Gastric Cancer Treatment

Fineline Cube Jan 5, 2024

Akeso Biopharma (HKG: 9926), a leading biopharmaceutical company based in China, has announced the submission...

Company Drug

JW Therapeutics Secures NMPA Review for CAR-T Therapy in Mantle Cell Lymphoma

Fineline Cube Jan 5, 2024

JW Therapeutics (HKG: 2126), a Chinese biopharmaceutical company, has announced that it has submitted an...

Hospital Policy / Regulatory

China’s Ministry of Education Launches Professional Guidelines for Healthcare Talent Training

Fineline Cube Jan 5, 2024

The Ministry of Education (MoE) in China has issued a Notice outlining the “Professional Guidelines...

Company Drug

Jiangsu Hengrui Pharmaceuticals Advances Novel Cancer Therapies with NMPA Clinical Trial Approval

Fineline Cube Jan 5, 2024

Jiangsu Hengrui Pharmaceuticals Co., Ltd (SHA: 600276) has received approval from the National Medical Products...

Company Deals

Suzhou Elite Analytical Instruments Secures Over $14 Million in Initial Funding Round

Fineline Cube Jan 5, 2024

Suzhou Elite Analytical Instruments Co., Ltd, a leading specialist in liquid chromatography based in China,...

Company Drug

Jiangsu Vcare PharmaTech Submits NDA to US FDA for Vicagrel, a P2Y12 Receptor Antagonist

Fineline Cube Jan 5, 2024

Jiangsu Vcare PharmaTech Co., Ltd, a Chinese pharmaceutical company, has submitted a New Drug Application...

Company Deals

Allorion Therapeutics and Avenzo Seal Deal for Global Rights to CDK2 Inhibitor

Fineline Cube Jan 5, 2024

China-based Allorion Therapeutics has entered into a licensing agreement with Avenzo Therapeutics Inc., granting the...

Company Drug

BMS’s Sotyktu, First TYK2 Inhibitor, Hits Chinese Market

Fineline Cube Jan 5, 2024

US pharmaceutical giant Bristol Myers Squibb (BMS, NYSE: BMY) has announced the market launch of...

Legal / IP

China’s National People’s Congress Approves Stricter Punishments for Sector-Specific Bribery

Fineline Cube Jan 4, 2024

The 7th meeting of the 14th National People’s Congress Standing Committee has passed the latest...

Company Deals Legal / IP

Daiichi Sankyo and Esperion Therapeutics Amend Collaboration on Antilipidemic Drugs

Fineline Cube Jan 4, 2024

Daiichi Sankyo (TYO: 4568)’s European subsidiary, a Japanese pharmaceutical company, has entered into a collaboration...

Posts pagination

1 … 464 465 466 … 710

Recent updates

  • China’s CDE Opens Public Comment on “Pioneer Program” for Cell and Gene Therapy Products, Capping Intake at 15 Drugs Per Year
  • CARsgen 1H 2026: Satricabtagene Autoleucel Wins NMPA Approval as World’s First CAR‑T for Solid Tumors; Cash Runway Seen Into 2030
  • Abbisko Wins NMPA IND Clearance for Pan‑KRAS Inhibitor ABSK211 in Advanced Solid Tumors, Following FDA Green Light
  • VectorBuilder and Lir Therapeutics Forge AI Collaboration to Optimize AAV Capsids for Clinical Translation
  • Ascentage Pharma 1H 2026: Revenue Jumps 29% to RMB 302 Million as Olverembatinib and Lisaftoclax Power Commercial Growth
Special Report 2025 Q1: U.S. Targets Chinese Pharma with 200% Tariffs—Will the Global Drug Market Collapse?

Category

  • Company
  • Deals
  • Digital
  • Drug
  • General/Other
  • Hospital
  • Legal / IP
  • Medical Device
  • Others
  • Policy / Regulatory
  • R&D

You Missed

Company Policy / Regulatory

China’s CDE Opens Public Comment on “Pioneer Program” for Cell and Gene Therapy Products, Capping Intake at 15 Drugs Per Year

Company

CARsgen 1H 2026: Satricabtagene Autoleucel Wins NMPA Approval as World’s First CAR‑T for Solid Tumors; Cash Runway Seen Into 2030

Company Drug

Abbisko Wins NMPA IND Clearance for Pan‑KRAS Inhibitor ABSK211 in Advanced Solid Tumors, Following FDA Green Light

Company Deals

VectorBuilder and Lir Therapeutics Forge AI Collaboration to Optimize AAV Capsids for Clinical Translation

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

Copyright © 2025 | Fineline Information & Technology | BlogData by Themeansar.